the aid library

LIST OPTIONS

Filter

774

Sort by:

Direction:

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (126)

View PDF (122)

Déclaration sur le traitement de médicaments maladie noveau Coronavirus (COVID-19)

Le centre Africain de prévention et de lutte contre la maladie (CDC Afrique); Union Africaine (2020) C_CDC

CDC Afrique est préoccupé par les informations inexactes distribués par les médias traditionnels et sociaux en ce qui concerne la prévention et le traitement des maladies nouvelles coronavirus (Covid-19). Sur la base d’un examen des preuves et de l’évaluation d’experts, le CDC Afrique r... more

Download (108)

View PDF (146)

Statement on medications to treat Novel Coronavirus disease (COVID-19)

Africa Centres for Disease Control and Prevention (Africa CDC) (2020) C_CDC

The Africa Centres for Disease Control and Prevention (Africa CDC) is concerned about inaccurate information being distributed through traditional and social media regarding prevention and treatment of novel coronavirus disease (COVID-19).

Download (994)

View PDF (914)

Stock Control Card_Form

Ecumenical Pharmaceutical Network (EPN) (2011) C2

Last revised 2015. Original Word document on: http://www.epnetwork.org/Resources/Standard%20Operating%20Procedure/Stock%20Control%20Card_Form.doc

Download (78)

View PDF (210)

Just had the COVID-19 vaccine? Well done and thank you!

Wesern Cape Government, South Africa (2021) CC

24 May 2021

Download (484)

View PDF (802)

After a Child's Immunisation - English
recommended

Auckland Regional Public Health Service (2016) C1

More information and languages can be found here: http://www.refugeehealth.govt.nz/resources/leaflets-and-fact-sheets/leaflets-by-topic/babies-and-children

Download (937)

View PDF (2766)

Cholera central reference kit - Item list

World Health Organization WHO (2015) C_WHO

Revised list

Download (279)

View PDF (547)

India: Integrated Management of Neonatal and Childhood Illness (f-IMNCI) - Participant's Manual (Module 7/9)

Ministry of Health and Family Welfare, Government of India; WHO; UNICEF (2009) C_WHO

Download (322)

View PDF (554)

India: Integrated Management of Neonatal and Childhood Illness - Treat the Child (Module 7/9)

Ministry of Health and Family Welfare, Government of India; WHO; UNICEF (2009) C_WHO

Download (503)

View PDF (158)

Предложение для всех, кто хочет помочь близким людям. Алкоголь, медикаменты, никотин, наркотики, зависимое поведение
recommended

К.ф.н. Рафаель Гассманн, К.ест.н. Кристине Хуттерер, Регина Мюллер et al. Deutsche Hauptstelle für Suchtfragen e.V., BZgA (2014) C1

Как близкий человека, страдающего наркоманией или находящегося под угрозой, вы находитесь в тяжёлом положении. Вы хотите понять его и помочь жить нормальной семей�... more

Download (110)

View PDF (193)

Guidelines for Management of COVID-19 in Children (below 18 years)

Ministry of Health& Family Welfare, Goverment of India (2021) CC

18 June 2021

Download (146)

View PDF (998)

A Concise Quality Control Guide on Essential Drugs and other Medicines

Jähnke, R.W.O. and Kornelia Dwornik (2021) CC

100 test methods for 100 active pharmaceutical ingredients For existing Minilab projects that want to replace old manuals or initiatives that want to start new projects, the new "Minilab Edition 2020" can be obtained at the preferential price of 50 € from our logistic partner Technologie Transfer... more

Download (120)

View PDF (982)

Control Visual y Cromatografía en Capa Fina

Jähnke, R.W.O. and Kornelia Dwornik (2021) CC

100 métodos de ensayo para 100 principios activos farmacéuticos Para los proyectos Minilab existentes que quieran sustituir los manuales antiguos o las iniciativas que quieran iniciar nuevos proyectos, el nuevo "Minilab Edition 2020" puede obtenerse al precio preferente de 50 euros de nuestro soc... more

Download (104)

View PDF (114)

Declaração sobre Medicamentos para o Tratamento da nova doença de Coronavírus (COVID-19)

Africa Centres for Disease Control and Prevention (Africa CDC); Centro Africano de prevenção e luta contra doenças ; União Africana (2020) C_CDC

O Centro Africano de Prevenção e Luta contra Doenças (CDC-África) está preocupado com a divulgação de informações incorrectas através de meios de comunicação tradicionais e sociais sobre a prevenção e o tratamento de nova doença de coronavírus (COVID-19).

Download (81)

View PDF (126)

Centros de controle e prevenção de doenças de Àfrica (África CDC) protocolo para o reforço da vigilância de doenças respiratórias agudas e doenças associadas à gripe para o COVID-19 em África

Centros de controle e prevenção de doenças de Àfrica (África CDC); União Africa (2020) C_CDC

Março de 2020 O número de Estados Membros da União Africana a reportarem casos do COVID-19 está a aumentar e existe uma probabilidade de transmissão comunitária. A OMS modificou recentemente a definição de caso suspeito do COVID-19, de modo a incluir infecção respiratória aguda grave... more